114 related articles for article (PubMed ID: 37544503)
21. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL; McPherson HR; Kettlewell L; Shnyder SD; Hurst CD; Alder O; Knowles MA
BMC Cancer; 2016 Jul; 16():553. PubMed ID: 27465249
[TBL] [Abstract][Full Text] [Related]
23. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
[TBL] [Abstract][Full Text] [Related]
25. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.
Sathe A; Guerth F; Cronauer MV; Heck MM; Thalgott M; Gschwend JE; Retz M; Nawroth R
Br J Cancer; 2014 Nov; 111(11):2103-13. PubMed ID: 25349966
[TBL] [Abstract][Full Text] [Related]
26. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.
Reddy OL; Cates JM; Gellert LL; Crist HS; Yang Z; Yamashita H; Taylor JA; Smith JA; Chang SS; Cookson MS; You C; Barocas DA; Grabowska MM; Ye F; Wu XR; Yi Y; Matusik RJ; Kaestner KH; Clark PE; DeGraff DJ
Am J Pathol; 2015 May; 185(5):1385-95. PubMed ID: 25907831
[TBL] [Abstract][Full Text] [Related]
27. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Zeng SX; Zhu Y; Ma AH; Yu W; Zhang H; Lin TY; Shi W; Tepper CG; Henderson PT; Airhart S; Guo JM; Xu CL; deVere White RW; Pan CX
Clin Cancer Res; 2017 Nov; 23(21):6580-6591. PubMed ID: 28808038
[No Abstract] [Full Text] [Related]
28. Activating Mutations in
Shin MK; Payne S; Bilger A; Matkowskyj KA; Carchman E; Meyer DS; Bentires-Alj M; Deming DA; Lambert PF
Clin Cancer Res; 2019 Mar; 25(6):1889-1900. PubMed ID: 30530704
[TBL] [Abstract][Full Text] [Related]
29. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
[TBL] [Abstract][Full Text] [Related]
31. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
32. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
[TBL] [Abstract][Full Text] [Related]
33. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
[TBL] [Abstract][Full Text] [Related]
34. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
Dai YC; Wang SC; Haque MM; Lin WH; Lin LC; Chen CH; Liu YW
PLoS One; 2017; 12(10):e0186214. PubMed ID: 29016672
[TBL] [Abstract][Full Text] [Related]
35. Divergent molecular profile of PIK3CA gene in arsenic-associated bladder carcinoma.
Basu M; Chakraborty B; Ghosh S; Samadder S; Dutta S; Roy A; Pal DK; Ghosh A; Panda CK
Mutagenesis; 2020 Dec; 35(6):499-508. PubMed ID: 33400797
[TBL] [Abstract][Full Text] [Related]
36. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
[TBL] [Abstract][Full Text] [Related]
37. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Cufí S; Corominas-Faja B; Lopez-Bonet E; Bonavia R; Pernas S; López IÁ; Dorca J; Martínez S; López NB; Fernández SD; Cuyàs E; Visa J; Rodríguez-Gallego E; Quirantes-Piné R; Segura-Carretero A; Joven J; Martin-Castillo B; Menendez JA
Oncotarget; 2013 Sep; 4(9):1484-95. PubMed ID: 23986086
[TBL] [Abstract][Full Text] [Related]
38. Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
Li WM; Hu TT; Zhou LL; Feng YM; Wang YY; Fang J
BMC Cancer; 2016 Jul; 16():454. PubMed ID: 27405731
[TBL] [Abstract][Full Text] [Related]
39. Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models.
Zupančič D; Kreft ME; Romih R
Protoplasma; 2014 Jan; 251(1):49-59. PubMed ID: 23828036
[TBL] [Abstract][Full Text] [Related]
40. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
